Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Mauro Magnani, Francesco Graziano et al.|British Journal of Cancer|2017Cited by 68
Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 studyCesare Gridelli, Ciro Gallo, Emiddio Barletta et al.|British Journal of Cancer|2001Cited by 17
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Eriseld Krasniqi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Enzo Veltri, Eriseld Krasniqi et al.|Frontiers in Oncology|2023Cited by 9